These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 31163241

  • 1. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study.
    Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM.
    J Am Acad Dermatol; 2019 Oct; 81(4):923-930. PubMed ID: 31163241
    [Abstract] [Full Text] [Related]

  • 2. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
    Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, Fuxench ZC, Harrington CL, Hubbard RA, Kalb RE, Menter A, Rader DJ, Reilly MP, Simpson EL, Takeshita J, Torigian DA, Werner TJ, Troxel AB, Tyring SK, Vanderbeek SB, Van Voorhees AS, Playford MP, Ahlman MA, Alavi A, Gelfand JM.
    Circ Cardiovasc Imaging; 2018 Jun; 11(6):e007394. PubMed ID: 29776990
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
    Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.
    Arch Dermatol; 2012 Apr; 148(4):487-94. PubMed ID: 22508874
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Apr; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 7. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar 01; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 8. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec 01; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 9. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW, Villanueva Quintero DG, Echeverría CM, Gu Y, Karunaratne M, Reyes Servín O.
    Am J Clin Dermatol; 2016 Dec 01; 17(6):691-699. PubMed ID: 27815915
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    JAMA Dermatol; 2018 Jun 01; 154(6):676-683. PubMed ID: 29799960
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis.
    Bagel J.
    J Drugs Dermatol; 2011 Apr 01; 10(4):366-71. PubMed ID: 21455546
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Adalimumab Compared With Methotrexate or Placebo Stratified by Baseline BMI in a Randomized Placebo-Controlled Trial in Patients With Psoriasis.
    Prussick R, Unnebrink K, Valdecantos WC.
    J Drugs Dermatol; 2015 Aug 01; 14(8):864-8. PubMed ID: 26267731
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study).
    Koek MB, Sigurdsson V, van Weelden H, Steegmans PH, Bruijnzeel-Koomen CA, Buskens E.
    BMJ; 2010 Apr 20; 340():c1490. PubMed ID: 20406865
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 20; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 15. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, Okun MM, Papp KA.
    J Am Acad Dermatol; 2011 Apr 20; 64(4):671-81. PubMed ID: 21414495
    [Abstract] [Full Text] [Related]

  • 16. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.
    Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043
    [Abstract] [Full Text] [Related]

  • 17. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Sep 27; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, Li S, Kimball AB.
    J Am Acad Dermatol; 2017 Mar 27; 76(3):405-417. PubMed ID: 28057360
    [Abstract] [Full Text] [Related]

  • 19. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW.
    J Dermatolog Treat; 2020 Sep 27; 31(6):617-623. PubMed ID: 31305186
    [Abstract] [Full Text] [Related]

  • 20. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T.
    J Dermatolog Treat; 2017 Sep 27; 28(6):488-491. PubMed ID: 28042711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.